WASHINGTON – The Drug Enforcement Administration will host public listening sessions to receive comments from healthcare practitioners, experts, advocates, patients, and other members of the public to inform DEA’s regulations on prescribing controlled substances via telemedicine. The listening sessions will be held in person and livestreamed with remote participation available. WHAT: Public Listening Sessions on Telemedicine ...

FROM THE DRUG POLICY ALLIANCE: The U.S. House will vote on the HALT Fentanyl Act tomorrow. This misguided bill would ramp up harsh mandatory minimum sentences for fentanyl analogues. And it would permanently make all fentanyl-related substances Schedule I without first testing them for benefits or harm.  Criminalization has failed to keep us safer. Instead, it’s actually fueling ...

CSAM is now accepting nomination submissions for the Vernelle Fox & Community Service Awards! Honoring an Inquiring Mind, Courage, and Enthusiasm Inquiring Mind – Contributions to the understanding of the field Courage – Resolution and tenacity Enthusiasm – Energy for the positive CSAM recognizes physicians who have made noteworthy and lasting contributions in line with the mission of the Society: ...

CSAM News: The Voice for Treatment | Spring 2023 Included in this issue: Letter from the CSAM President, Karen Miotto, Message from the CSAM Conference Committee Chair, MERF Update, How I Ended Up in Addiction Medicine by CSAM President Elect Sharone Abramowitz MD FASAM, CSAM Government Affairs Committee Update, Case Discussions are Back! by CSAM Secretary ...

Governor Newsom has invested over $1 billion to tackle the crisisThrough CalRx, California will seek to manufacture its own NaloxoneMaster Plan provides comprehensive approach to save more lives SAN DIEGO COUNTY – Today, following a visit to the San Ysidro Port of Entry, Governor Gavin Newsom released his administration’s Master Plan for Tackling the Fentanyl and ...

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.” All DEA registrants should be aware of the following: A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder. Going forward, all prescriptions for buprenorphine only require a standard DEA registration ...

After almost twenty years of intense medication specific government regulation buprenorphine is now just like other schedule III medications. The era of limited numbers of treatment slots that started at 30 patients per provider who had completed 8 hours of specific training, requirements to maintain lists of patients who received prescriptions and even in person visits ...